Département de Pharmacologie-Physiologie, Institut de Pharmacologie de Sherbrooke, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, 3001, 12th Avenue North, Sherbrooke, QC, J1H 5N4, Canada.
J Neural Transm (Vienna). 2020 Apr;127(4):661-672. doi: 10.1007/s00702-020-02172-4. Epub 2020 Mar 18.
The use of opioids for the relief of pain and headache disorders has been studied for years. Nowadays, particularly because of its ability to produce analgesia in various pain models, delta opioid receptor (DOPr) emerges as a promising target for the development of new pain therapies. Indeed, their potential to avoid the unwanted effects commonly observed with clinically used opioids acting at the mu opioid receptor (MOPr) suggests that DOPr agonists could be a therapeutic option. In this review, we discuss the use of opioids in the management of pain in addition to describing the evidence of the analgesic potency of DOPr agonists in animal models.
阿片类药物在缓解疼痛和头痛障碍方面的应用已经研究了多年。如今，特别是由于其在各种疼痛模型中产生镇痛作用的能力，δ 阿片受体（DOPr）作为开发新的疼痛疗法的有前途的靶点而出现。事实上，它们有可能避免临床上使用作用于μ阿片受体（MOPr）的阿片类药物常见的不良反应，这表明 DOPr 激动剂可能是一种治疗选择。在这篇综述中，我们讨论了阿片类药物在疼痛管理中的应用，同时还描述了 DOPr 激动剂在动物模型中镇痛效力的证据。
